{"hands_on_practices": [{"introduction": "The 'triple assessment'—clinical exam, mammography, and ultrasound—is a cornerstone of evaluating breast lumps. This exercise explores the critical question of what to do when all three components are negative. By applying Bayesian principles through the use of likelihood ratios, you will learn to precisely quantify the post-test probability of malignancy, a foundational skill for confidently determining when a patient's risk is low enough to safely defer a biopsy [@problem_id:4602970].", "problem": "A patient in a general surgery clinic is evaluated for a new, nonbloody, nonnipple-discharge breast lump. Based on population-level data and clinical context, the pretest probability of malignancy is assessed as $P(\\text{cancer}) = 0.05$. Three diagnostic modalities are obtained and yield negative results: clinical breast examination, diagnostic mammography, and targeted breast ultrasound. The operating characteristics (assumed known from meta-analytic data and stable across this context) are sensitivity/specificity pairs of clinical breast examination $0.60/0.90$, mammography $0.85/0.90$, and ultrasound $0.80/0.85$. Assume conditional independence of these tests given disease status.\n\nUsing only the core definitions of sensitivity and specificity and Bayes theorem (via odds and likelihood ratios), derive the post-test probability $P(\\text{cancer} \\mid \\text{all three negative})$ under the conditional independence assumption. Express your final numerical answer as an exact reduced fraction (no rounding).\n\nThen, starting from first principles of expected loss minimization in binary decisions, justify the existence of a management threshold probability below which benign management without biopsy is acceptable. Specifically, derive a symbolic expression for the threshold probability $p^{\\ast}$ at which the expected loss of performing an immediate biopsy equals that of observation, in terms of two quantities: the expected loss of an unnecessary biopsy when the state is benign, $C_{\\text{over}}$, and the expected loss from delayed diagnosis if the state is malignant, $C_{\\text{miss}}$. Do not insert numerical values for $C_{\\text{over}}$ or $C_{\\text{miss}}$ in your derivation; your derivation must show how $p^{\\ast}$ arises from the fundamental decision rule. The final numeric answer to submit is the post-test probability only.", "solution": "The problem is valid. It is a well-posed application of Bayesian inference and decision theory to a clinical scenario. The data provided are self-contained and consistent, and the assumptions (e.g., conditional independence) are explicitly stated, allowing for a unique and meaningful solution. The problem is scientifically grounded in the principles of medical diagnostics and decision analysis.\n\nThe problem consists of two parts. First, we must calculate the post-test probability of malignancy given three negative diagnostic tests. Second, we must derive a symbolic expression for the management threshold probability from first principles of expected loss minimization.\n\n### Part 1: Calculation of Post-Test Probability\n\nLet $C$ denote the event that the patient has cancer, and $\\neg C$ be the event that the patient's condition is benign. The pre-test probability is given as $P(C) = 0.05$. This implies the probability of a benign condition is $P(\\neg C) = 1 - P(C) = 1 - 0.05 = 0.95$.\n\nThe problem specifies using the odds and likelihood ratio formulation of Bayes' theorem. The pre-test odds of cancer are defined as the ratio of the probability of having cancer to the probability of not having it:\n$$\n\\text{Odds}_{\\text{pre}} = \\frac{P(C)}{P(\\neg C)} = \\frac{0.05}{0.95} = \\frac{5}{95} = \\frac{1}{19}\n$$\n\nNext, we calculate the likelihood ratio for a negative test result ($LR^-$) for each of the three diagnostic modalities. The sensitivity (Se) of a test is $P(\\text{test}+ \\mid C)$, and the specificity (Sp) is $P(\\text{test}- \\mid \\neg C)$. The likelihood ratio for a negative result is defined as:\n$$\nLR^- = \\frac{P(\\text{test}- \\mid C)}{P(\\text{test}- \\mid \\neg C)}\n$$\nThe numerator, the probability of a negative test given cancer, is the false negative rate, which is $1 - \\text{Se}$. The denominator is the true negative rate, which is the specificity, Sp. Therefore:\n$$\nLR^- = \\frac{1 - \\text{Se}}{\\text{Sp}}\n$$\n\nWe are given the following sensitivity/specificity pairs:\n1.  Clinical Breast Examination (CBE): $\\text{Se}_{\\text{CBE}} = 0.60$, $\\text{Sp}_{\\text{CBE}} = 0.90$.\n2.  Diagnostic Mammography (MG): $\\text{Se}_{\\text{MG}} = 0.85$, $\\text{Sp}_{\\text{MG}} = 0.90$.\n3.  Targeted Breast Ultrasound (US): $\\text{Se}_{\\text{US}} = 0.80$, $\\text{Sp}_{\\text{US}} = 0.85$.\n\nUsing these values, we calculate the $LR^-$ for each test:\n$$\nLR^-_{\\text{CBE}} = \\frac{1 - 0.60}{0.90} = \\frac{0.40}{0.90} = \\frac{4}{9}\n$$\n$$\nLR^-_{\\text{MG}} = \\frac{1 - 0.85}{0.90} = \\frac{0.15}{0.90} = \\frac{15}{90} = \\frac{1}{6}\n$$\n$$\nLR^-_{\\text{US}} = \\frac{1 - 0.80}{0.85} = \\frac{0.20}{0.85} = \\frac{20}{85} = \\frac{4}{17}\n$$\n\nThe problem states to assume conditional independence of the tests given the disease status. This means that the combined likelihood ratio for all three tests being negative ($E$) is the product of the individual likelihood ratios:\n$$\nLR^-_{\\text{combined}} = LR^-_{\\text{CBE}} \\times LR^-_{\\text{MG}} \\times LR^-_{\\text{US}}\n$$\n$$\nLR^-_{\\text{combined}} = \\frac{4}{9} \\times \\frac{1}{6} \\times \\frac{4}{17} = \\frac{16}{918} = \\frac{8}{459}\n$$\n\nThe post-test odds are found by multiplying the pre-test odds by the combined likelihood ratio:\n$$\n\\text{Odds}_{\\text{post}} = \\text{Odds}_{\\text{pre}} \\times LR^-_{\\text{combined}}\n$$\n$$\n\\text{Odds}_{\\text{post}} = \\frac{1}{19} \\times \\frac{8}{459} = \\frac{8}{8721}\n$$\n\nFinally, we convert the post-test odds back to a probability. If $\\text{Odds} = O$, the probability $P$ is given by $P = \\frac{O}{1+O}$.\n$$\nP(C \\mid E) = \\frac{\\text{Odds}_{\\text{post}}}{1 + \\text{Odds}_{\\text{post}}} = \\frac{\\frac{8}{8721}}{1 + \\frac{8}{8721}} = \\frac{\\frac{8}{8721}}{\\frac{8721+8}{8721}} = \\frac{8}{8729}\n$$\nThe numerator is $8 = 2^3$. The denominator $8729$ is not even. The sum of its digits is $8+7+2+9=26$, which is not divisible by $3$. Further factorization shows $8729 = 7 \\times 29 \\times 43$. Since the numerator and denominator share no common factors, the fraction is fully reduced.\n\n### Part 2: Derivation of the Management Threshold Probability\n\nThis part requires deriving the threshold probability $p^{\\ast}$ at which a decision-maker is indifferent between performing an immediate biopsy and observation. This is a classic decision analysis problem. Let $p$ be the probability of malignancy (e.g., the post-test probability calculated above).\n\nThe two states of nature are Malignant ($M$) and Benign ($B$). The probabilities are $P(M) = p$ and $P(B) = 1-p$.\nThe two possible actions are Biopsy ($Bx$) and Observe ($Obs$).\n\nWe define a loss function $L(\\text{Action}, \\text{State})$ that quantifies the negative consequence of each action-state pair. We can normalize the loss for correct decisions to zero:\n- $L(Bx, M) = 0$ (correctly biopsying a cancer)\n- $L(Obs, B) = 0$ (correctly observing a benign lesion)\n\nThe problem defines two loss quantities:\n- $C_{\\text{over}}$: the loss of an unnecessary biopsy when the state is benign. This corresponds to $L(Bx, B) = C_{\\text{over}}$.\n- $C_{\\text{miss}}$: the loss from delayed diagnosis if the state is malignant. This corresponds to $L(Obs, M) = C_{\\text{miss}}$.\n\nThe decision rule is to choose the action that minimizes the expected loss. The expected loss for each action is the sum of the losses for each state, weighted by the probability of that state.\n\nExpected Loss of Biopsy:\n$$\nE[L(Bx)] = L(Bx, M) P(M) + L(Bx, B) P(B)\n$$\n$$\nE[L(Bx)] = (0 \\times p) + (C_{\\text{over}} \\times (1-p)) = C_{\\text{over}}(1-p)\n$$\n\nExpected Loss of Observation:\n$$\nE[L(Obs)] = L(Obs, M) P(M) + L(Obs, B) P(B)\n$$\n$$\nE[L(Obs)] = (C_{\\text{miss}} \\times p) + (0 \\times (1-p)) = C_{\\text{miss}} p\n$$\n\nThe threshold probability $p^{\\ast}$ is the value of $p$ at which the decision-maker is indifferent between the two actions, meaning their expected losses are equal:\n$$\nE[L(Bx)] = E[L(Obs)]\n$$\n$$\nC_{\\text{over}}(1-p^{\\ast}) = C_{\\text{miss}} p^{\\ast}\n$$\nWe solve for $p^{\\ast}$:\n$$\nC_{\\text{over}} - C_{\\text{over}}p^{\\ast} = C_{\\text{miss}} p^{\\ast}\n$$\n$$\nC_{\\text{over}} = C_{\\text{miss}} p^{\\ast} + C_{\\text{over}}p^{\\ast}\n$$\n$$\nC_{\\text{over}} = p^{\\ast}(C_{\\text{miss}} + C_{\\text{over}})\n$$\n$$\np^{\\ast} = \\frac{C_{\\text{over}}}{C_{\\text{over}} + C_{\\text{miss}}}\n$$\nThis expression is the symbolic representation of the management threshold probability.\n\nThe existence of this threshold justifies benign management without biopsy when the probability of malignancy $p$ is below $p^{\\ast}$. The decision rule is:\n- If $p  p^{\\ast}$, then $C_{\\text{miss}} p  C_{\\text{over}}(1-p)$, so $E[L(Obs)]  E[L(Bx)]$. The optimal action is to Observe.\n- If $p  p^{\\ast}$, then $C_{\\text{miss}} p  C_{\\text{over}}(1-p)$, so $E[L(Obs)]  E[L(Bx)]$. The optimal action is to Biopsy.\n\nThis completes the derivation from first principles. The final numeric answer required is only the post-test probability from Part 1.", "answer": "$$\n\\boxed{\\frac{8}{8729}}\n$$", "id": "4602970"}, {"introduction": "While standard imaging is often sufficient, some clinical presentations, like pathologic nipple discharge, require more advanced diagnostics. This practice examines the impact of a positive MRI when other tests are negative, a common and challenging clinical scenario. You will use conditional probability to calculate how this single finding drastically revises the risk of cancer and, just as importantly, provides a definitive target for surgical excision, transforming the management plan [@problem_id:4602973].", "problem": "A patient presents with spontaneous unilateral, single-duct nipple discharge that is serosanguinous and persistent, with normal findings on clinical examination and mammography and ultrasonography. In the context of pathologic nipple discharge, assume the pre-test probability (baseline prevalence) of carcinoma is $0.05$. Magnetic Resonance Imaging (MRI) for occult breast lesions in this setting has sensitivity $0.90$ and specificity $0.80$. The MRI is positive for a focal enhancing retroareolar lesion consistent with an intraductal process.\n\nUsing only core definitions of sensitivity, specificity, and conditional probability, compute the post-test probability of carcinoma given the positive MRI. Express the final probability as a decimal and round your answer to four significant figures. Then, explain how this updated probability, together with the nature of pathologic discharge and the ability to localize a lesion on MRI, should inform the decision to proceed to targeted duct excision versus continued observation.", "solution": "The problem statement is scientifically and mathematically valid. It presents a realistic clinical scenario in breast surgery and provides a self-contained, consistent set of data for a probabilistic calculation. All necessary information is provided for a unique solution.\n\nLet $C$ be the event that the patient has carcinoma, and $\\neg C$ be the event that the patient does not have carcinoma. Let $MRI+$ be the event of a positive Magnetic Resonance Imaging (MRI) result. The problem provides the following givens:\n\n1.  The pre-test probability (prevalence) of carcinoma is $P(C) = 0.05$.\n2.  The sensitivity of the MRI is the probability of a positive result given that carcinoma is present: $P(MRI+ | C) = 0.90$.\n3.  The specificity of the MRI is the probability of a negative result given that carcinoma is absent: $P(MRI- | \\neg C) = 0.80$.\n\nOur objective is to compute the post-test probability of carcinoma given the positive MRI result, which is denoted as $P(C | MRI+)$. We will use the definition of conditional probability and the law of total probability.\n\nFirst, we determine the probabilities of the complementary events. The pre-test probability of not having carcinoma is:\n$$P(\\neg C) = 1 - P(C) = 1 - 0.05 = 0.95$$\n\nThe specificity gives us $P(MRI- | \\neg C) = 0.80$. The probability of a positive MRI result given that carcinoma is absent (the false positive rate) is the complement of the specificity:\n$$P(MRI+ | \\neg C) = 1 - P(MRI- | \\neg C) = 1 - 0.80 = 0.20$$\n\nAccording to the definition of conditional probability, the post-test probability is:\n$$P(C | MRI+) = \\frac{P(C \\cap MRI+)}{P(MRI+)}$$\n\nThe numerator, $P(C \\cap MRI+)$, which is the joint probability of having carcinoma and a positive MRI, can be rewritten using the definition of conditional probability for sensitivity:\n$$P(C \\cap MRI+) = P(MRI+ | C) P(C)$$\n\nThe denominator, $P(MRI+)$, is the total probability of a positive MRI result. It can be calculated using the law of total probability by considering the two mutually exclusive scenarios: the patient has carcinoma, or the patient does not have carcinoma.\n$$P(MRI+) = P(MRI+ \\cap C) + P(MRI+ \\cap \\neg C)$$\nUsing the definition of conditional probability on each term:\n$$P(MRI+) = P(MRI+ | C) P(C) + P(MRI+ | \\neg C) P(\\neg C)$$\n\nNow, we substitute the given values into this equation to find the total probability of a positive MRI:\n$$P(MRI+) = (0.90)(0.05) + (0.20)(0.95)$$\n$$P(MRI+) = 0.045 + 0.190$$\n$$P(MRI+) = 0.235$$\n\nWith the values for $P(C \\cap MRI+)$ and $P(MRI+)$, we can now compute the post-test probability $P(C | MRI+)$:\n$$P(C | MRI+) = \\frac{P(MRI+ | C) P(C)}{P(MRI+)} = \\frac{(0.90)(0.05)}{0.235} = \\frac{0.045}{0.235}$$\n$$P(C | MRI+) \\approx 0.19148936...$$\nRounding to four significant figures, the post-test probability of carcinoma is $0.1915$.\n\nRegarding the clinical decision-making process:\nThe computed post-test probability of $0.1915$, or $19.15\\%$, represents a substantial increase from the initial pre-test probability of $5\\%$. A nearly $1$-in-$5$ chance of malignancy is clinically significant and warrants definitive action to rule out cancer.\n\nThe decision between targeted duct excision and continued observation is informed by two key outcomes of the MRI: the updated probability and the localization of a lesion.\n1.  **Risk Stratification:** The increase in probability from $5\\%$ to $19.15\\%$ elevates the level of suspicion from low to moderate-to-high. Continued observation in the face of such a risk, particularly for a treatable condition like breast cancer, is not a prudent clinical strategy. The potential harm of a delayed diagnosis far outweighs the risks of a minimally invasive surgical procedure.\n2.  **Lesion Localization:** The most critical contribution of the positive MRI in this specific clinical context is the identification and localization of a \"focal enhancing retroareolar lesion.\" The initial workup with mammography and ultrasonography was normal, meaning the source of the pathologic discharge was \"occult.\" Without a target, a surgeon would have to perform a major duct excision, a more extensive and less precise procedure involving the removal of the central duct system \"blindly.\" The MRI has provided a precise target. This allows for a targeted surgical approach, such as an MRI-guided wire localization followed by an excisional biopsy of the specific lesion and associated duct.\n\nIn conclusion, the combination of a significantly increased probability of carcinoma and, crucially, the new ability to target the causative lesion makes targeted duct excision the unequivocally indicated next step. This procedure serves as both a diagnostic tool, providing tissue for definitive histopathological analysis, and a therapeutic intervention to resolve the nipple discharge. Continued observation would be contrary to the standard of care.", "answer": "$$\n\\boxed{0.1915}\n$$", "id": "4602973"}, {"introduction": "Clinical guidelines, such as the six-month follow-up for Breast Imaging-Reporting and Data System (BI-RADS) category 3 lesions, are fundamental to practice, but their quantitative basis is not always transparent. This exercise moves beyond diagnostic probabilities to explore the biophysical principles that underpin surveillance protocols. By modeling tumor volume growth, you will derive the 'delay-to-detection harm' and thereby provide a mechanistic justification for why a six-month interval balances prudent monitoring against excessive imaging [@problem_id:4602881].", "problem": "A surgeon is evaluating the rationale for a six-month follow-up interval for Breast Imaging-Reporting and Data System (BI-RADS) category 3 “probably benign” lesions. Consider a mechanistic model grounded in two well-tested biological and physical principles:\n\n- Tumor growth can be approximated over short intervals by exponential growth in volume characterized by a constant volume doubling time.\n- For a roughly spherical lesion, volume is proportional to the cube of diameter, that is, if diameter is $d(t)$ at time $t$, then $V(t) \\propto d(t)^{3}$.\n\nAssume the following for a single BI-RADS category 3 lesion measured at baseline:\n\n- Baseline diameter $d_{0} = 7\\,\\text{mm}$.\n- If the lesion is malignant, its constant volume doubling time $D$ (in days) is unknown but lies uniformly in the interval $[100,200]$.\n- The lesion is clinically considered to cross a management-relevant threshold upon reaching diameter $d_{\\text{thr}} = 10\\,\\text{mm}$.\n- The planned follow-up delay is $t_{\\text{delay}} = 180\\,\\text{days}$.\n- The prevalence of malignancy among BI-RADS category 3 lesions is $p_{\\text{mal}} = 0.02$.\n\nUsing only the assumptions above and the principles stated, define the “delay-to-detection harm” as the expected fraction of all BI-RADS category 3 patients in whom a malignant lesion (if present) would cross from $d_{0}$ to at least $d_{\\text{thr}}$ during the $t_{\\text{delay}}$ interval before repeat imaging.\n\nUnder exponential volume growth with constant $D$ and spherical geometry, derive an analytic expression for this expected fraction and evaluate it numerically for the parameters given. Express the final expected fraction as a decimal rounded to four significant figures. Do not use a percentage sign.", "solution": "The problem is first validated to ensure it is scientifically grounded, well-posed, and objective.\n\n### Step 1: Extract Givens\n-   **Principle 1**: Tumor volume growth is exponential with a constant volume doubling time, $D$.\n-   **Principle 2**: For a spherical lesion, volume $V(t)$ is proportional to the cube of the diameter $d(t)$: $V(t) \\propto d(t)^{3}$.\n-   **Baseline diameter**: $d_{0} = 7\\,\\text{mm}$.\n-   **Volume doubling time**: For malignant lesions, $D$ is a random variable uniformly distributed in the interval $[100, 200]$ days. Let this interval be $[D_{\\min}, D_{\\max}]$, so $D_{\\min} = 100\\,\\text{days}$ and $D_{\\max} = 200\\,\\text{days}$.\n-   **Threshold diameter**: $d_{\\text{thr}} = 10\\,\\text{mm}$.\n-   **Follow-up delay**: $t_{\\text{delay}} = 180\\,\\text{days}$.\n-   **Prevalence of malignancy**: The probability that a BI-RADS category 3 lesion is malignant is $p_{\\text{mal}} = 0.02$.\n-   **Definition of \"delay-to-detection harm\"**: The expected fraction of all BI-RADS category 3 patients in whom a malignant lesion crosses from $d_0$ to at least $d_{thr}$ during the $t_{delay}$ interval.\n\n### Step 2: Validate Using Extracted Givens\n-   **Scientifically Grounded**: The model's assumptions—exponential growth for volume and spherical geometry—are standard and reasonable approximations used in oncologic modeling, particularly over short time frames. The given numerical values for diameters, doubling times, and prevalence are within clinically realistic ranges. The problem is based on established biophysical modeling principles.\n-   **Well-Posed**: The problem is fully specified. It provides all necessary parameters, defines the random variable's distribution, and gives a clear, quantifiable objective. A unique, stable, and meaningful solution can be derived.\n-   **Objective**: The problem is stated in precise, quantitative, and unbiased language. The definition of \"harm\" is provided explicitly within the context of the model, avoiding subjective interpretation.\n\n### Step 3: Verdict and Action\nThe problem is valid. It is a well-posed, scientifically grounded problem in applied mathematics and biophysics. A full solution will be derived.\n\n### Derivation of the Solution\n\nThe solution proceeds by first establishing the mathematical relationship for diameter growth, then determining the condition for crossing the threshold, and finally calculating the required probability.\n\nLet $V(t)$ be the volume of the lesion at time $t$ and $d(t)$ be its diameter. The starting time is $t=0$, with initial diameter $d(0) = d_0$ and initial volume $V(0) = V_0$.\n\n**1. Model Tumor Growth**\nExponential volume growth with a constant doubling time $D$ is described by the equation:\n$$ V(t) = V_0 \\cdot 2^{t/D} $$\nThis can be expressed using the natural exponential function. Since $2 = \\exp(\\ln(2))$, we have:\n$$ V(t) = V_0 \\exp\\left(\\frac{t \\ln(2)}{D}\\right) $$\n\n**2. Relate Volume to Diameter**\nThe lesion is assumed to be spherical. The volume of a sphere with diameter $d$ is $V = \\frac{4}{3}\\pi\\left(\\frac{d}{2}\\right)^3 = \\frac{\\pi}{6}d^3$.\nThus, the relationship between volume and diameter at any time $t$ is:\n$$ \\frac{V(t)}{V_0} = \\frac{\\frac{\\pi}{6}d(t)^3}{\\frac{\\pi}{6}d_0^3} = \\left(\\frac{d(t)}{d_0}\\right)^3 $$\n\n**3. Derive Diameter Growth Equation**\nBy equating the two expressions for the volume ratio $V(t)/V_0$, we get:\n$$ \\left(\\frac{d(t)}{d_0}\\right)^3 = \\exp\\left(\\frac{t \\ln(2)}{D}\\right) $$\nTaking the cube root of both sides gives the ratio of diameters:\n$$ \\frac{d(t)}{d_0} = \\left[\\exp\\left(\\frac{t \\ln(2)}{D}\\right)\\right]^{1/3} = \\exp\\left(\\frac{t \\ln(2)}{3D}\\right) $$\nSo, the diameter at time $t$ is given by:\n$$ d(t) = d_0 \\exp\\left(\\frac{t \\ln(2)}{3D}\\right) $$\n\n**4. Determine the Condition for Crossing the Threshold**\nThe lesion crosses the management-relevant threshold if its diameter $d(t)$ reaches or exceeds $d_{\\text{thr}}$ within the follow-up interval $t_{\\text{delay}}$. The condition is $d(t_{\\text{delay}}) \\ge d_{\\text{thr}}$.\nSubstituting the expression for $d(t_{\\text{delay}})$:\n$$ d_0 \\exp\\left(\\frac{t_{\\text{delay}} \\ln(2)}{3D}\\right) \\ge d_{\\text{thr}} $$\nWe need to solve this inequality for the doubling time $D$. Since $D$ is a random variable, this inequality defines the subset of outcomes corresponding to the \"harm\" event for a malignant lesion.\n$$ \\exp\\left(\\frac{t_{\\text{delay}} \\ln(2)}{3D}\\right) \\ge \\frac{d_{\\text{thr}}}{d_0} $$\nTaking the natural logarithm of both sides:\n$$ \\frac{t_{\\text{delay}} \\ln(2)}{3D} \\ge \\ln\\left(\\frac{d_{\\text{thr}}}{d_0}\\right) $$\nSince $d_{\\text{thr}}  d_0$, the term $\\ln(d_{\\text{thr}}/d_0)$ is positive. We can rearrange the inequality to solve for $D$:\n$$ D \\le \\frac{t_{\\text{delay}} \\ln(2)}{3 \\ln(d_{\\text{thr}}/d_0)} $$\nThis inequality shows that the harm occurs if the doubling time $D$ is less than or equal to a critical value, which we define as $D_{\\text{crit}}$:\n$$ D_{\\text{crit}} = \\frac{t_{\\text{delay}} \\ln(2)}{3 \\ln(d_{\\text{thr}}/d_0)} $$\n\n**5. Calculate the Probability of Harm for a Malignant Lesion**\nThe doubling time $D$ for a malignant lesion is a random variable uniformly distributed on the interval $[D_{\\min}, D_{\\max}]$, i.e., $[100, 200]$. The probability density function (PDF) is:\n$$ f(D) = \\frac{1}{D_{\\max} - D_{\\min}} \\quad \\text{for } D \\in [D_{\\min}, D_{\\max}] $$\nThe probability that a given malignant lesion will cross the threshold is the probability that its doubling time $D$ is less than or equal to $D_{\\text{crit}}$, written as $P(D \\le D_{\\text{crit}})$.\nFirst, we compute the value of $D_{\\text{crit}}$ using the given parameters:\n$$ D_{\\text{crit}} = \\frac{180 \\cdot \\ln(2)}{3 \\cdot \\ln(10/7)} = \\frac{60 \\ln(2)}{\\ln(10/7)} $$\nNumerically, $\\ln(2) \\approx 0.693147$ and $\\ln(10/7) \\approx 0.356675$.\n$$ D_{\\text{crit}} \\approx \\frac{60 \\times 0.693147}{0.356675} \\approx 116.6015\\,\\text{days} $$\nSince $D_{\\min} = 100  D_{\\text{crit}}  D_{\\max} = 200$, the range of \"harmful\" doubling times partially overlaps with the distribution of $D$. The probability $P(D \\le D_{\\text{crit}})$ for a malignant lesion is the length of the interval $[D_{\\min}, D_{\\text{crit}}]$ divided by the length of the total interval $[D_{\\min}, D_{\\max}]$:\n$$ P(D \\le D_{\\text{crit}}) = \\frac{D_{\\text{crit}} - D_{\\min}}{D_{\\max} - D_{\\min}} = \\frac{116.6015 - 100}{200 - 100} = \\frac{16.6015}{100} = 0.166015 $$\n\n**6. Calculate the Final Expected Fraction**\nThe problem asks for the expected fraction of *all* BI-RADS category 3 patients who experience this outcome. This is the joint probability of two events: (1) the lesion is malignant, and (2) the malignant lesion's doubling time is in the harmful range.\nLet $F$ be the desired fraction.\n$$ F = p_{\\text{mal}} \\times P(D \\le D_{\\text{crit}}) $$\nSubstituting the values:\n$$ F = 0.02 \\times 0.166015 = 0.0033203 $$\nThe analytic expression for the expected fraction is:\n$$ F = p_{\\text{mal}} \\left( \\frac{\\frac{t_{\\text{delay}} \\ln(2)}{3 \\ln(d_{\\text{thr}}/d_0)} - D_{\\min}}{D_{\\max} - D_{\\min}} \\right) $$\nThis expression is valid under the condition $D_{\\min} \\le D_{\\text{crit}} \\le D_{\\max}$, which has been verified.\nRounding the numerical result to four significant figures gives $0.003320$.", "answer": "$$\n\\boxed{0.003320}\n$$", "id": "4602881"}]}